3 results
Primary Study ObjectiveTo assess the non-inferiority of the 12-week triptorelin formulation Pamorelin® 11,25 mg administered via subcutaneous (SC) injection as compared to Pamorelin® 11,25 mg administered via registered intramuscular (IM) injection…
The purpose of this study is to evaluate the effect of high dose RAS-antagonists and beta-blocker treatment for the primary prevention of cardiac events in a population of patients with Type 2 diabetes mellitus (T2DM) with no evidence of a…
Primary Efficacy Objectives:* To demonstrate the decrease in anti-fXa activity following andexanet treatment.* To evaluate the hemostatic efficacy following andexanet treatment.Secondary Efficacy Objective:* To assess the relationship between…